Hemony Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and sales, headquartered in Chongqing and Shanghai, with subsidiaries in Germany, Switzerland, Hong Kong and Taiwan.

As a pioneer to practice the Marketing Authorization Holder (MAH) system in domestic China, Hemony has a wealth of experience in merging and acquiring mature pharmaceutical assets from multinational pharmaceutical companies.In recent years, our company has merged and acquired the superior products of numerous multinational pharmaceutical corporations. For example, Novartis' Baclofen Tablets in Switzerland, Wyeth's Multivitamin Elemental Tablets in the United States, Takeda's Calcium Carbonate D3 Chewable Tablets in Japan, STADA's Lipoic Acid Injection in Germany, Herbrand's Propylthiouracil Tablets in Germany, Lotuspharm’s Mesyrel in Taiwan region, Synmosa’s Budesonide Nasal Spray in Taiwan Drospirenone Ethinylestradiol Tablets from Chemo, Spain, etc.

The company focuses on psychiatry, otorhinolaryngology, obstetrics and gynecology, orthopaedics and other disease fields. The hospital business has set up specialized, obstetrics and gynecology, comprehensive business departments, and the out-of-hospital business includes OTC and clinic teams, forming a two-wheel-driven development pattern inside and outside the hospital.

With the mission of “All Efforts for Health”, with the vision of “Strive to become a medical enterprise with leading commercialization capabilities, highly respected in the industry, and all employees who feel happy", with core value of “Be highly aimed and pragmatic, be innovative and tolerant, be cooperative&honest and trustworthy”, Hemony will always exert to provide people with high quality pharmaceutical products and services.